Friedreich's Ataxia

🧠 Standard of Care & Symptoms

Friedreich's Ataxia (FA) is the most common hereditary ataxia, characterized by progressive spinocerebellar neurodegeneration, sensory neuropathy, and severe extraneural complications.

• Presentation: Key neurological, skeletal, and systemic signs.
  • Neurological Decline: Progressive gait and limb ataxia starting before age 25. Slurred or jerky speech (cerebellar dysarthria), loss of position (proprioception) and vibration sensation, absent deep tendon reflexes (loss of knee/ankle jerks), and progressive weakness.
  • Skeletal Deformities: Characteristic high-arched feet (**pes cavus**), hammer toes, and progressive scoliosis (spine curvature) which can compromise pulmonary function.
  • Hypertrophic Cardiomyopathy: Present in over 90% of patients. Hypertrophy of the left ventricle and septum can cause arrhythmias, Heart Failure, and is the leading cause of premature mortality.
  • Diabetes Mellitus: Affects 10-20% of patients due to mitochondrial dysfunction leading to progressive pancreatic beta-cell loss and peripheral insulin resistance.

🧬 Diagnostics & FXN GAA Repeat Pathology

Diagnosis is suspected based on early-onset progressive ataxia with loss of reflexes, and confirmed through molecular genetic testing of the FXN gene.

• Genetic Test: Confirms a homozygous **GAA trinucleotide repeat expansion** in intron 1 of the **FXN** gene on chromosome 9q21.11. Affected individuals have between 70 to over 1000 GAA repeats (normal is ≤ 30). Longer repeat lengths correlate with earlier onset and more severe disease.
• Electrodiagnostics: Sensory nerve conduction studies show absent or severely reduced sensory nerve action potentials (SNAPs) with preserved motor conduction.
• Cardiac Screening: Echocardiogram documents concentric left ventricular hypertrophy.

Pathophysiology & Mitochondrial Frataxin Silencing

The cellular degeneration in Friedreich's Ataxia is driven by mitochondrial iron overload and oxidative stress:

• FXN Silencing: The GAA repeat expansion forms sticky triplex DNA structures and recruits histone methyltransferases/deacetylases. This causes local heterochromatin formation, transcriptionally silencing the **FXN** gene and leading to a severe deficiency of the protein **frataxin**.
• Iron-Sulfur (Fe-S) Cluster Dysfunction: Frataxin is an essential mitochondrial protein that acts as an iron chaperone involved in the biogenesis of iron-sulfur (Fe-S) clusters. Fe-S clusters are vital cofactors for mitochondrial respiratory chain complexes (I, II, and III) and aconitase.
• Mitochondrial Damage & Neurodegeneration: In the absence of frataxin, free iron accumulates inside the mitochondria. This iron reacts with oxygen (Fenton chemistry) to generate highly toxic reactive oxygen species (ROS), causing oxidative damage and respiratory chain failure. This selectively destroys the large sensory neurons in the dorsal root ganglia (DRG), the spinocerebellar tracts, the lateral corticospinal tracts, and the dorsal columns of the spinal cord.

💊 Nrf2 Activators & Cardiomyopathy Management

Treatment combines targeted pharmacotherapy to restore mitochondrial function with proactive screening for heart disease and diabetes.

Targeted Disease-Modifying Therapy

• Omaveloxolone: Approved in 2023. Omaveloxolone is a small molecule that activates the **Nrf2** (nuclear factor erythroid 2-related factor 2) transcription factor. Nrf2 activation upregulates antioxidant enzymes, restores mitochondrial electron transport chain function, and reduces oxidative stress. In clinical trials, it significantly slowed the rate of neurological decline.

Cardiac and Supportive Care

• Beta-Blockers & ACE Inhibitors: Prescribed to manage hypertrophic cardiomyopathy, control arrhythmias, and prevent Heart Failure.
• Physical and Occupational Therapy: Essential to maintain core strength, manage spasticity, and implement assistive mobility devices (weighted walkers, wheelchairs).
• Endocrine Monitoring: Routine fasting blood glucose or HbA1c tests to identify and manage diabetes early using insulin or oral sensitizers.

🔬 Active Clinical Trials

Clinical trials are currently evaluating adeno-associated virus (AAV) gene therapies to restore FXN expression in cardiac and neural tissue, novel mitochondrial antioxidants, and digital gait sensors.

🗺️ Next Steps After Diagnosis

If you or a loved one have recently been diagnosed with Friedreich's Ataxia, establish these care pathways:

1. Verify GAA Repeat Length: Complete genetic testing to document your repeat numbers, which helps predict clinical progression.
2. Schedule a Cardiac Echocardiogram and ECG: Establish a baseline heart profile with a cardiologist to monitor for wall thickening.
3. Discuss Omaveloxolone (Skyclarys): Ask your neurologist if you are a candidate for this FDA-approved Nrf2 activator to slow progression.
4. Initiate Physical Therapy: Start targeted exercises early to focus on gait safety, core stability, and stretching to prevent contractures.

❓ Patient FAQ

Q: What is the cause of Friedreich's Ataxia? Is it inherited?
A: Yes, Friedreich's Ataxia is an autosomal recessive genetic disorder. This means a person must inherit two mutated copies of the **FXN** gene (one from each parent) to develop the disease. The mutation is a "GAA repeat expansion," where a three-letter genetic code (G-A-A) is repeated hundreds of times inside the gene. This expansion blocks the cell from reading the gene, resulting in a severe shortage of the protein **frataxin**, leading to cell damage in the nerves and heart.

Q: Why does a nerve disease affect the heart?
A: The genetic mutation in Friedreich's Ataxia causes a deficiency in **frataxin**, a protein that cells need to keep their powerhouses—the mitochondria—working safely. Cells that require a massive amount of energy to function (like the large sensory nerves in the spinal cord and the muscle cells of the heart) are highly sensitive to mitochondrial damage. Without frataxin, iron builds up in cardiac mitochondria, causing toxic stress that leads to heart muscle thickening (hypertrophic cardiomyopathy).